About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2013 (2013), Article ID 725305, 19 pages
http://dx.doi.org/10.1155/2013/725305
Research Article

Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

1Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex HA6 1BN, UK
2School of Biomedical Sciences, King’s College, London SE1 1UL, UK
3Palliative Care Department, Royal Marsden Hospital, London SW3 6JJ, UK
4Sarcoma Unit, Royal Marsden Hospital, London SW3 6JJ, UK

Received 13 May 2013; Accepted 20 August 2013

Academic Editor: R. Pollock

Copyright © 2013 Julian F. Guest et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Julian F. Guest, Monica Panca, Erikas Sladkevicius, Nicholas Gough, and Mark Linch, “Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden,” Sarcoma, vol. 2013, Article ID 725305, 19 pages, 2013. doi:10.1155/2013/725305